Athyrium Capital Management, LP

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 8, 2024), Athyrium Capital Management, LP reported 2 stock positions worth $11.3 million. Its top holding was Biora Therapeutics at 63.8% of the portfolio, followed by Puma Biotechnology (PBYI, 36.2%). Its holdings were unchanged from Q1 2024.

Most Recent 13F
Q3 2024
Location
New York, NY
CIK
0001728001
Portfolio Value
$11.3M (Q2 2024)
SEC Filing
0001123292-24-000213 ↗ filed Aug 8, 2024

Holdings Value

0$5.0M$10.0M$15.0M$20.0M Q1 2024: $18.7M Q1 2024 Q2 2024: $11.3M $11.3M Q2 2024 Q3 2024: $8.7M Q3 2024

Holdings 2 stocks · $11.3M
BIORA THERAPEUTICS INC 63.78% 10,929,762 $7.2M No change
PBYI Puma Biotechnology Inc. 36.22% 1,256,411 $4.1M No change
Other holdings (1): bonds, preferreds, convertibles and warrants · $22.2M (not counted above)
SecurityClassShares / PrincipalValueChange
COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) NOTE 1.500% 4/1 · principal 30,000,000$22.2MNew

Total filed on the 13F, all lines: $33.5M.

Portfolio Sells Q1 2024 → Q2 2024
None this quarter.

Portfolio Buys Q1 2024 → Q2 2024
None this quarter.

Notes & Other Activity Q1 2024 → Q2 2024
OMEROS CORP (OMER 5.25 02/15/26) NOTE 5.250% 2/1 · principal Sold out 72,979,000 $54.1Mbefore exit
COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) NOTE 1.500% 4/1 · principal New 30,000,000 $22.2M

Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 2$8.7MBIORA THERAPEUTICS INC, PBYI
Q2 2024 2$11.3MBIORA THERAPEUTICS INC, PBYI
Q1 2024 2$18.7MBIORA THERAPEUTICS INC, PBYI